Aspirin + Ticagrelor
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Saphenous Vein Graft Disease
Conditions
Saphenous Vein Graft Disease
Trial Timeline
Sep 1, 2014 → Aug 1, 2021
NCT ID
NCT02053909About Aspirin + Ticagrelor
Aspirin + Ticagrelor is a approved stage product being developed by AstraZeneca for Saphenous Vein Graft Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02053909. Target conditions include Saphenous Vein Graft Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02053909 | Approved | Completed |
Competing Products
2 competing products in Saphenous Vein Graft Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Atorvastatin 80 mg daily + Atorvastatin 10 mg daily | Pfizer | Phase 3 | 76 |
| Alirocumab 150 MG/ML subcutaneous injection + Matching Placebo subcutaneous injection | Regeneron Pharmaceuticals | Approved | 84 |